Home > Insider Trading > Filing (0001487371-21-000007)

Filing Details

Accession Number:: 0001487371-21-000007
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-21 20:09:53
Reporting Period:: 2021-01-19

Accepted Time:: 2021-01-21 20:09:53
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1487371	Genmark Diagnostics Inc.	GNMK	Surgical & Medical Instruments & Apparatus (3841)	272053069

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1515051	Scott Mendel	5964 La Place Court Carlsbad CA 92008	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-01-19	50,000	$14.54	115,491	No	4	S	Indirect	Mendel Trust dated October 14, 2011
Common Stock	Acquisiton	2021-01-21	50,074	$0.00	446,904	No	4	M	Direct
Common Stock	Acquisiton	2021-01-21	46,098	$0.00	493,002	No	4	M	Direct
Common Stock	Acquisiton	2021-01-21	50,000	$0.00	543,002	No	4	M	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	Mendel Trust dated October 14, 2011
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Market Stock Units	Disposition	2021-01-21	50,074	$0.00	50,074	$0.00
Common Stock	Market Stock Units	Disposition	2021-01-21	46,098	$0.00	46,098	$0.00
Common Stock	Market Stock Units	Disposition	2021-01-21	50,000	$0.00	50,000	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	No	4	M	Direct
14,167	No	4	M	Direct
50,000	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	396,830	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by reporting person in July 2020.
The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $14.09 to $14.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Mr. Mendel is the trustee of the Mendel Trust and has voting and dispositive power with respect to these shares. Mr. Mendel disclaims beneficial ownership except to the extent of his pecuniary interest therein.
The MSUs vested in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third annual performance periods, the Reporting Person was eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares based on the Issuer's three-year total Shareholder return, as compared to the Nasdaq Composite Index.
The MSUs vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares based on the Issuer's two-year total Shareholder return, as compared to the Nasdaq Composite Index.
Represents the target number of shares which remain subject to the award.
The MSUs vest in three equal installments, on each of December 31, 2020, December 31, 2021, and December 31, 2022; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares based on the Issuer's one-year total Shareholder return, as compared to the Nasdaq Composite Index.